ArticlePhysics and imaging in radiation oncology2025
Cost-effectiveness of personalized policies for implementing organ-at-risk sparing adaptive radiation therapy in head and neck cancer.
Article in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Visualization-driven digital technologies in oncology: current applications, technological advances, and future directions.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Background and Purpose: The principle of adaptive radiation therapy (ART) is to adjust radiation plans in response to anatomical changes during treatment. The purpose of this study was to develop a decision-making model for implementation of personalized ART that balances the costs and clinical benefits of radiation plan adaptations in head and neck cancer (HNC). Materials and Methods: Using retrospective imaging data from 52 HNC patients, a Markov decision process (MDP) model was developed to determine optimal timing for plan adaptations based on the difference in normal tissue complication probability (ΔNTCP) between planned and delivered doses to organs-at-risk. To capture the trade-off between the costs and benefits of plan adaptations, the end-treatment ΔNTCPs were converted to Quality Adjusted Life Years (QALYs) and then to equivalent monetary values using a willingness-to-pay per QALY parameter. Results: The optimal policies were derived for 96 combinations of willingness-to-pay per QALY (W) and re-planning cost (RC) and validated using Monte Carlo simulation for two representative scenarios: (1) W = $200,000, RC = $1,000; (2) W = $100,000, RC = $2,000. In scenario (1), the MDP model's policy reduced the probability of excessive toxicity (ΔNTCP ≥ 5 %) to zero (from 0.21 without re-planning) at an average cost of $380 per patient. In scenario (2), it reduced this probability to 0.02 at an average cost of $520 per patient. Conclusions: The MDP model's policies outperformed the current fixed-time (one-size-fits-all) approaches in both clinical and financial outcomes in the simulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.